Laya Kiani
Laya Kiani is a blogger at CCRM, focusing on creating content about the market analysis of regenerative medicine. With over four years of experience in health care and marketing across Canada, Dubai and Iran, she brings a diverse perspective to her work. Laya holds a B.Sc. in Pharmaceutical Chemistry from the University of Guelph. Connect with her on LinkedIn: LayaKiani
Posts by: Laya
The non-dilutive funding path for biotech startups
Are you an early-stage startup founder looking for funding options without giving up equity? If so, non-dilutive funding may be the solution you need. It allows startups to advance research, build credibility and move closer to commercialization while maintaining full ownership. In life sciences, these funds help startups progress through development without carrying the full […]
Beyond cryptocurrency, how blockchain is transforming science, research and biotech funding
We’ve all heard about Bitcoin—the first decentralized cryptocurrency. From overnight millionaires to market crashes, crypto has been a rollercoaster ride. Since 2008, cryptocurrencies have introduced a new era in the financial sector by enabling transactions without the involvement of any third party. But what if blockchain technology could do more than just disrupt banking? What […]
The impact of IPOs on biotech market expansion: Strategies and projections
The biotechnology sector has always been a hub of innovation, consistently pushing the boundaries of scientific and technological advancements. However, transforming novel discoveries into viable market-ready solutions requires substantial financial backing. Among the different ways biotech and pharmaceutical companies secure long-term financial stability, Initial Public Offerings (IPOs) have become a key strategy for raising capital […]
CGT dealmaking outlook: 2025 review and expectations for 2026
In 2025, cell and gene therapy (CGT) showed growing clinical familiarity even as access and reimbursement challenges persisted. Providers and payers increasingly trusted and valued CGTs, supporting the continued expansion of late-stage programs. However, startup activity remained muted amid economic uncertainty, regulatory shifts, evolving therapeutic priorities and increasingly selective investors. Even though total deal value […]